Literature DB >> 24048330

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.

Laszlo Radvanyi1, Shari Pilon-Thomas, Weiyi Peng, Amod Sarnaik, James J Mulé, Jeffrey Weber, Patrick Hwu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24048330      PMCID： PMC3823378          DOI： 10.1158/1078-0432.CCR-13-1054

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

2.  Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Authors:  Shari Pilon-Thomas; Amy Mackay; Nasreen Vohra; James J Mulé
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

3.  Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Authors:  Stephen R Goding; Kyle A Wilson; Ying Xie; Kristina M Harris; Aparna Baxi; Akgul Akpinarli; Amy Fulton; Koji Tamada; Scott E Strome; Paul Andrew Antony
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

4.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Authors:  Weiyi Peng; Chengwen Liu; Chunyu Xu; Yanyan Lou; Jieqing Chen; Yan Yang; Hideo Yagita; Willem W Overwijk; Gregory Lizée; Laszlo Radvanyi; Patrick Hwu
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

5.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531
  5 in total
  8 in total

1.  Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.

Authors:  Yang Du; Ting Sun; Xiaolong Liang; Yuan Li; Zhengyu Jin; Huadan Xue; Yihong Wan; Jie Tian
Journal:  Int J Nanomedicine       Date:  2017-11-21

2.  Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.

Authors:  Kaiyuan Wang; Jian Wang; Feng Wei; Ning Zhao; Fan Yang; Xiubao Ren
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

3.  Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.

Authors:  Baihui Li; Bailu Zhang; Xuezhou Wang; Ziqing Zeng; Ziqi Huang; Lin Zhang; Feng Wei; Xiubao Ren; Lili Yang
Journal:  Oncoimmunology       Date:  2020-08-28       Impact factor: 8.110

4.  A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.

Authors:  Jian-Feng Li; Yuan-Yuan Niu; Yan-Li Xing; Feng Liu
Journal:  Biosci Rep       Date:  2019-05-31       Impact factor: 3.840

5.  Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.

Authors:  Xuhan Zhang; Lu Liu; Shiyong Zhou; Kuo Zhao; Zheng Song; Ge Hu; Tingting Zhang; Yang Li; Lihua Qiu; Lanfang Li; Zhengzi Qian; Bin Meng; Yi Pan; Xiubao Ren; Xianhuo Wang; Huilai Zhang; Kai Fu
Journal:  Hematol Oncol       Date:  2019-05-30       Impact factor: 5.271

6.  A prognostic model for melanoma patients on the basis of immune-related lncRNAs.

Authors:  Yao Wang; Hong-Jun Ba; Xi-Zhi Wen; Min Zhou; Can Küçük; Luca Tamagnone; Li Wei; Hua You
Journal:  Aging (Albany NY)       Date:  2021-03-06       Impact factor: 5.682

7.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.

Authors:  Zipei Feng; Sachin Puri; Tarsem Moudgil; William Wood; Clifford C Hoyt; Chichung Wang; Walter J Urba; Brendan D Curti; Carlo B Bifulco; Bernard A Fox
Journal:  J Immunother Cancer       Date:  2015-10-20       Impact factor: 13.751

Review 8.  Immune Checkpoint Molecules in Reproductive Immunology.

Authors:  Eva Miko; Matyas Meggyes; Katalin Doba; Aliz Barakonyi; Laszlo Szereday
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.